To evaluate the growth inhibition effect of Azenosertib on OV90 cells, results showed that Azenosertib treatment resulted in partial growth inhibition or cytostatic effect.
NPJ Precis Oncol. 2025 Jan 4;9(1):3
OVCAR4
1.3 nM to 10 μM
72 h
To evaluate the growth inhibition effect of Azenosertib on OVCAR4 cells, results showed that Azenosertib treatment resulted in significant cytotoxicity.
NPJ Precis Oncol. 2025 Jan 4;9(1):3
OVCAR3
1.3 nM to 10 μM
72 h
To evaluate the growth inhibition effect of Azenosertib on OVCAR3 cells, results showed that Azenosertib treatment resulted in significant cytotoxicity.
NPJ Precis Oncol. 2025 Jan 4;9(1):3
NCI-H2122
250 nM
24 h
Evaluate the synergistic effect of Azenosertib combined with KRASG12C inhibitors, showing significant increases in DNA damage and apoptosis markers (γH2AX and c-Casp-3/7).
Cancer Res Commun. 2025 Feb 1;5(2):240-252
Azenosertib 动物实验
Species
Animal Model
Administration
Dosage
Frequency
Description
References
NOD/SCID mice
OVCAR3 xenograft model
Oral
80 mg/kg
Once daily for 28 days
To evaluate the anti-tumor activity of Azenosertib in the OVCAR3 xenograft model, results showed that a dose of 80 mg/kg resulted in 88% tumor growth inhibition.
NPJ Precis Oncol. 2025 Jan 4;9(1):3
Mice
H358 xenograft model
Oral
60 mg/kg
5 days per week for 3–5 weeks
ZN-c3 monotherapy and combination with sotorasib effectively suppressed tumor growth
Cell Rep Med. 2024 Jun 18;5(6):101578
NOD/SCID mice
NCI-H2122 CDX model
Oral
60 mg/kg
Once daily for 25 days
Evaluate the antitumor activity of Azenosertib alone and in combination with sotorasib, showing complete tumor regression (104% TGI) with combination therapy.
搜索
